{"organizations": [], "uuid": "25d94dca35d0a52c0169cebae713d696fd845880", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-us-fda-clears-pluristems-phase-iii/brief-u-s-fda-clears-pluristems-phase-iii-study-in-treatment-of-muscle-injury-following-hip-fracture-surgery-idUSASC09X9M", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T14:06:00.000+03:00", "replies_count": 0, "uuid": "25d94dca35d0a52c0169cebae713d696fd845880"}, "author": "", "url": "https://www.reuters.com/article/brief-us-fda-clears-pluristems-phase-iii/brief-u-s-fda-clears-pluristems-phase-iii-study-in-treatment-of-muscle-injury-following-hip-fracture-surgery-idUSASC09X9M", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "treatment of muscle inj", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "hip fracture surgery reuters", "sentiment": "none"}, {"name": "pluristem therapeutics inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Pluristem Therapeutics Inc:\n* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY\n* PLURISTEM THERAPEUTICS INC - IN DISCUSSIONS WITH SEVERAL EU COUNTRIES TO APPROVE STUDY IN EUROPE\n* PLURISTEM THERAPEUTICS INC - EXPECTS TO BEGIN PATIENT ENROLLMENT IN BOTH EUROPE AND U.S. DURING 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": [], "published": "2018-04-25T14:06:00.000+03:00", "crawled": "2018-04-25T14:22:18.039+03:00", "highlightTitle": ""}